AstraZeneca PLC ADR (AZN): Price and Financial Metrics

AZN POWR Grades

• AZN scores best on the Growth dimension, with a Growth rank ahead of 89.75% of US stocks.
• The strongest trend for AZN is in Quality, which has been heading up over the past 177 days.
• AZN's current lowest rank is in the Momentum metric (where it is better than 9.57% of US stocks).

AZN Stock Summary

• AZN has a higher market value than 99.21% of US stocks; more precisely, its current market capitalization is $209,873,920,063.
• AZN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.07 -- higher than only 1.12% of US-listed equities with positive expected earnings growth.
• In terms of twelve month growth in earnings before interest and taxes, ASTRAZENECA PLC is reporting a growth rate of 61,911.11%; that's higher than 99.98% of US stocks.
• If you're looking for stocks that are quantitatively similar to ASTRAZENECA PLC, a group of peers worth examining would be NVS, PFE, NFLX, ABBV, and CSCO.
• AZN's SEC filings can be seen here. And to visit ASTRAZENECA PLC's official web site, go to www.astrazeneca.com.

AZN Valuation Summary

• AZN's price/sales ratio is 5; this is 127.27% higher than that of the median Healthcare stock.
• Over the past 243 months, AZN's price/earnings ratio has gone up 21.4.

Below are key valuation metrics over time for AZN.

AZN Growth Metrics

Its 3 year price growth rate is now at 74.78%.
• Its 3 year cash and equivalents growth rate is now at 39.31%.
• The 2 year cash and equivalents growth rate now stands at 68.83%.

Over the past 70 months, AZN's revenue has gone up $22,059,000,000.

The table below shows AZN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-12-31	44,351	9,808	3,288
2022-12-31	44,351	9,808	3,288
2022-09-30	45,154	8,828	2,039
2022-06-30	44,038	7,617	-1,253
2022-03-31	41,487	7,261	-1,063
2021-12-31	37,417	5,963	112

AZN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• AZN has a Quality Grade of B, ranking ahead of 78.56% of graded US stocks.
• AZN's asset turnover comes in at 0.438 -- ranking 104th of 681 Pharmaceutical Products stocks.
• CLVS, HSKA, and FLXN are the stocks whose asset turnover ratios are most correlated with AZN.

The table below shows AZN's key quality metrics over time.